MERUS N V's ticker is MRUS and the CUSIP is N5749R100. A total of 1 filers reported holding MERUS N V in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,465 | -89.9% | 1,292 | -88.7% | 0.00% | -90.0% |
| Q2 2023 | $300,425 | +834413.9% | 11,410 | +479.8% | 0.01% | +900.0% |
| Q1 2023 | $36 | +33.3% | 1,968 | +14.3% | 0.00% | 0.0% |
| Q4 2022 | $27 | -100.0% | 1,722 | -63.3% | 0.00% | -50.0% |
| Q3 2022 | $94,000 | +276.0% | 4,697 | +330.5% | 0.00% | +100.0% |
| Q2 2022 | $25,000 | -71.6% | 1,091 | -67.3% | 0.00% | 0.0% |
| Q1 2022 | $88,000 | +363.2% | 3,341 | +462.5% | 0.00% | – |
| Q4 2021 | $19,000 | -55.8% | 594 | -69.8% | 0.00% | -100.0% |
| Q3 2021 | $43,000 | +87.0% | 1,968 | +48.2% | 0.00% | 0.0% |
| Q4 2020 | $23,000 | +283.3% | 1,328 | +232.8% | 0.00% | – |
| Q2 2020 | $6,000 | -72.7% | 399 | -78.5% | 0.00% | -100.0% |
| Q1 2020 | $22,000 | -24.1% | 1,855 | -9.5% | 0.00% | -50.0% |
| Q4 2019 | $29,000 | -39.6% | 2,049 | -23.9% | 0.00% | -33.3% |
| Q3 2019 | $48,000 | +1500.0% | 2,692 | +1169.8% | 0.00% | – |
| Q2 2017 | $3,000 | -40.0% | 212 | -68.8% | 0.00% | – |
| Q2 2016 | $5,000 | – | 679 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 893,527 | $23,625,000 | 21.94% |
| Medicxi Ventures Management (Jersey) Ltd | 1,600,000 | $42,304,000 | 11.46% |
| COMMODORE CAPITAL LP | 1,816,421 | $48,026,000 | 10.73% |
| MPM BioImpact LLC | 919,482 | $24,311,000 | 6.52% |
| Aquilo Capital Management, LLC | 1,261,534 | $33,355,000 | 4.90% |
| BVF INC/IL | 4,135,071 | $109,331,000 | 4.37% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 324,719 | $8,586,000 | 3.55% |
| TCG Crossover Management, LLC | 300,000 | $7,932,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 235,500 | $6,227,000 | 2.91% |
| Opaleye Management Inc. | 338,000 | $8,937,000 | 2.78% |